Interactions between PPAR-α and inflammation-related cytokine genes on the development of Alzheimer's disease, observed by the Epistasis Project.

OBJECTIVE Neuroinflammation contributes to the pathogenesis of sporadic Alzheimer's disease (AD). Variations in genes relevant to inflammation may be candidate genes for AD risk. Whole-genome association studies have identified relevant new and known genes. Their combined effects do not explain 100% of the risk, genetic interactions may contribute. We investigated whether genes involved in inflammation, i.e. PPAR-α, interleukins (IL) IL- 1α, IL-1β, IL-6, and IL-10 may interact to increase AD risk. METHODS The Epistasis Project identifies interactions that affect the risk of AD. Genotyping of single nucleotide polymorphisms (SNPs) in PPARA, IL1A, IL1B, IL6 and IL10 was performed. Possible associations were analyzed by fitting logistic regression models with AD as outcome, controlling for centre, age, sex and presence of apolipoprotein ε4 allele (APOEε4). Adjusted synergy factors were derived from interaction terms (p<0.05 two-sided). RESULTS We observed four significant interactions between different SNPs in PPARA and in interleukins IL1A, IL1B, IL10 that may affect AD risk. There were no significant interactions between PPARA and IL6. CONCLUSIONS In addition to an association of the PPARA L162V polymorphism with the AD risk, we observed four significant interactions between SNPs in PPARA and SNPs in IL1A, IL1B and IL10 affecting AD risk. We prove that gene-gene interactions explain part of the heritability of AD and are to be considered when assessing the genetic risk. Necessary replications will require between 1450 and 2950 of both cases and controls, depending on the prevalence of the SNP, to have 80% power to detect the observed synergy factors.

[1]  P. Deloukas,et al.  Interaction of insulin and PPAR-α genes in Alzheimer’s disease: the Epistasis Project , 2012, Journal of Neural Transmission.

[2]  L. Polito,et al.  Interleukin-1α, interleukin-1β and tumor necrosis factor-α genetic variants and risk of dementia in the very old: evidence from the “Monzino 80-plus” prospective study , 2012, AGE.

[3]  S. Allan,et al.  Assessing the contribution of inflammation in models of Alzheimer's disease. , 2011, Biochemical Society transactions.

[4]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[5]  J Zhang,et al.  The −1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer's disease: A meta-analysis , 2011, Journal of the Neurological Sciences.

[6]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[7]  P. Bertolucci,et al.  Interleukin-8-251T > A, Interleukin-1α-889C > T and Apolipoprotein E polymorphisms in Alzheimer’s disease , 2010, Genetics and molecular biology.

[8]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Alzheimer's Disease , 2010, Biological Psychiatry.

[9]  P. Deloukas,et al.  The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project , 2010, BMC Medical Genetics.

[10]  Seth Love,et al.  Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease , 2010, PloS one.

[11]  Mario Cortina-Borja,et al.  Open Access Journal of Neuroinflammation Replication by the Epistasis Project of the Interaction between the Genes for Il-6 and Il-10 in the Risk of Alzheimer's Disease , 2022 .

[12]  Xiao-dan Jiang,et al.  Genetic Analysis of Interleukin-1A C(-889)T Polymorphism with Alzheimer Disease , 2009, Cellular and Molecular Neurobiology.

[13]  F. Sánchez-García,et al.  Cytokine IL‐1 beta but not IL‐1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain , 2008, European journal of neurology.

[14]  R. Maccioni,et al.  Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. , 2004, Experimental cell research.

[15]  W. Maier,et al.  Polymorphism in the peroxisome proliferator-activated receptor α gene influences the risk for Alzheimer’s disease , 2003, Journal of Neural Transmission.

[16]  F. Jessen,et al.  Association of an interleukin-1β gene polymorphism at position -511 with Alzheimer's disease , 2003 .

[17]  H. Möller,et al.  Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease , 2003, European Archives of Psychiatry and Clinical Neuroscience.

[18]  G. Landreth,et al.  Regulation of β-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor α , 2001, Neurochemistry International.

[19]  W. Maier,et al.  Gene polymorphisms of interleukin‐1α influence the course of Alzheimer's disease , 2001, Annals of neurology.

[20]  W. Oertel,et al.  Association of an interleukin 1α polymorphism with Alzheimer’s disease , 2000, Neurology.

[21]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[22]  F. Jessen,et al.  Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer's disease risk in a German population , 2000, Neuroscience Letters.

[23]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: insight into multiple cellular functions. , 2000, Mutation research.

[24]  M. Franceschi,et al.  Association of early‐onset Alzheimer's disease with an interleukin‐1α gene polymorphism , 2000, Annals of neurology.

[25]  G. Landreth,et al.  Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists , 2000, The Journal of Neuroscience.

[26]  F. Jessen,et al.  A genetic variation of the inflammatory cytokine interleukin‐6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease , 1999, Annals of neurology.

[27]  R. Skinner,et al.  In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis , 1996, Neurobiology of Aging.

[28]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[29]  X. Chen,et al.  Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[31]  W. Griffin,et al.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[33]  Nick C Fox,et al.  Common variants at ABCA 7 , MS 4 A 6 A / MS 4 A 4 E , EPHA 1 , CD 33 and CD 2 AP are associated with Alzheimer ’ s disease , 2011 .

[34]  Mario Cortina-Borja,et al.  The synergy factor: a statistic to measure interactions in complex diseases , 2009, BMC Research Notes.

[35]  Journal of Neuroinflammation BioMed Central , 2008 .

[36]  J. Wands,et al.  Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[37]  F. Jessen,et al.  Association of an interleukin-1beta gene polymorphism at position -511 with Alzheimer's disease. , 2003, International journal of molecular medicine.

[38]  G. Landreth,et al.  Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. , 2001, Neurochemistry international.

[39]  G. Landreth,et al.  Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  S. Paul,et al.  Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. , 2000, Neurology.